Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Terminated Phase 2 Interventional Results available

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00138125
View directory record Official record
Conditions
Breast Cancer
Interventions
Faslodex, Herceptin
Drug · Biological
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Redondo Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?

NCT00186524
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer Support Group
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Oct 30, 2026, 1:09 PM EDT
Terminated Not applicable Interventional Results available

Phyllodes Tumor Partial Breast Radiation Study

NCT01089374
View directory record Official record
Conditions
Phyllodes Tumor
Interventions
Partial breast radiation after lumpectomy
Radiation
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 30, 2026, 1:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

NCT07064018
View directory record Official record
Conditions
Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions
Spedox-6, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Not applicable Interventional

Patient Navigator Project

NCT00375024
View directory record Official record
Conditions
Breast Cancer, Colon Cancer
Interventions
Patient Navigation, Clinic Staff
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 30, 2026, 1:09 PM EDT
Active, not recruiting Phase 1 Interventional

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

NCT03716180
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Not applicable Interventional Results available

Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity

NCT05871125
View directory record Official record
Conditions
Breast Cancer
Interventions
Reimbursement
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 1:09 PM EDT
Recruiting Phase 2 Interventional

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

NCT05846789
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer, ER Positive, HER2 Negative Breast Cancer
Interventions
SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Atlanta, Georgia • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer

NCT00004013
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cone Beam Computed Tomography for Breast Imaging

NCT00972413
View directory record Official record
Conditions
Breast Cancer
Interventions
Computed Tomography
Radiation
Lead sponsor
Koning Corporation
Industry
Eligibility
40 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Venlafaxine for Hot Flashes After Breast Cancer

NCT00198250
View directory record Official record
Conditions
Breast Cancer
Interventions
venlafaxine
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2008 · Synced Oct 30, 2026, 1:09 PM EDT
Recruiting Phase 1 Interventional

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions
MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
Biological · Drug
Lead sponsor
Memgen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Tampa, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 1:09 PM EDT
Completed No phase listed Observational

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

NCT00006425
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Not applicable Interventional

POWER-remote Weight Loss Program in Early Stage Breast Cancer

NCT01871116
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
POWER-remote, Self-directed
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

NCT00228358
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 30, 2026, 1:09 PM EDT
Completed No phase listed Observational

Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study

NCT06463626
View directory record Official record
Conditions
Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 30, 2026, 1:09 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand

NCT04876378
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 30, 2026, 1:09 PM EDT
Terminated Phase 2 Interventional

Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

NCT00215748
View directory record Official record
Conditions
Breast Cancer, Lung Cancer
Interventions
Dexamethasone
Drug
Lead sponsor
Geriatric Oncology Consortium
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)

NCT00784849
View directory record Official record
Conditions
Breast Cancer
Interventions
Methylene blue
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
2
States / cities
Lafayette, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 30, 2026, 1:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Breast Cancer Surveillance Consortium

NCT01831778
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
2,345,817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 30, 2026, 1:09 PM EDT
Active, not recruiting No phase listed Observational

CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer

NCT04495985
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

NCT01446016
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Paclitaxel, Docetaxel, Abraxane, Ixabepilone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 30, 2026, 1:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747
View directory record Official record
Conditions
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Combination Product · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
32
States / cities
Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 1:09 PM EDT